FOR IMMEDIATE RELEASE
Jan. 21, 2021
MILWAUKEE – The Society for Immunotherapy of Cancer (SITC), the world’s leading membership-driven organization dedicated solely to cancer immunotherapy, is pleased to announce that Mary Dean, JD, CAE, has been named Executive Director of the association.
Ms. Dean steps into her new role after serving as the Associate Executive Director of SITC since February 2018, helping steward the strategic vision of the society as set forth by its members. She has more than 16 years of association experience. She spent the majority of those years serving as the Executive Director for the American Society of Gene & Cell Therapy, in addition to the Executive Director for the Society of Behavioral Medicine, American Venous Forum, and Growing Spine Foundation.
Ms. Dean assumes the lead staff role of the society from long-time SITC leader, Tara Withington, CAE, who served as its Executive Director since 2001. Mrs. Withington will continue to support the society’s efforts as Executive Director Emeritus/Consulting Partner.
“I am excited to have the opportunity to work hand-in-hand with Mary during my tenure over the next two years as we work to help achieve new heights for the society,” said SITC President Patrick Hwu, MD. “Like for most organizations, the coronavirus pandemic posed many challenges for SITC in 2020, and I was proud to see how Mary strategized and executed a number of initiatives to ensure that our society continued producing the high quality educational and scientific programming our members have come to expect. The future of SITC is bright under her leadership.”
SITC is a membership organization of more than 4,600 basic scientists, translational researchers, clinicians and many others who are dedicated to the advancement of immunotherapy as a means to treat cancer. SITC is managed by Executive Director, Inc. (EDI), an association management company that has provided professional service for international medical, certification and scientific association for more than 50 years.
“I am humbled and honored to serve as Executive Director for this society and the thousands of members who are all dedicated to one goal: seeking to make the word, ‘cure,’ a reality for cancer patients everywhere,” Dean said. “As we navigate a global pandemic, we can’t lose sight of the cancer pandemic that claims the lives of 600,000 patients every year. I look forward to working with the SITC members and staff as we strategize how to address the most critical scientific issues in the field.”
Ms. Dean earned a Bachelor of Arts degree in art history and environmental biology from Ripon College in Wisconsin before earning a Juris Doctor degree from Marquette University Law School in Milwaukee, Wis. She received a certified association executive (CAE) credential from the American Society of Association Executives (ASAE), and is a member of the American Bar Association (ABA) and Wisconsin Bar Association (WBA).
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.
# # #